DHR Stock Overview
Designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community Narratives
Narratives bring a range of perspectives from our community.
Innovations And Market Share Gains Fuel Optimistic Revenue And EPS Growth In Life Sciences
Danaher Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$266.06 |
| 52 Week High | US$281.70 |
| 52 Week Low | US$182.09 |
| Beta | 0.86 |
| 11 Month Change | -2.06% |
| 3 Month Change | 5.27% |
| 1 Year Change | 0.72% |
| 33 Year Change | -18.79% |
| 5 Year Change | 89.69% |
| Change since IPO | 29,905.03% |
Recent News & Updates
Here's Why Danaher (NYSE:DHR) Can Manage Its Debt Responsibly
Aug 28
Danaher: Lofty Price, Bright Future
Aug 22Danaher Corporation's (NYSE:DHR) Price In Tune With Earnings
Aug 13Recent updates
Here's Why Danaher (NYSE:DHR) Can Manage Its Debt Responsibly
Aug 28Danaher: Lofty Price, Bright Future
Aug 22Danaher Corporation's (NYSE:DHR) Price In Tune With Earnings
Aug 13Danaher: Valuation Now Too High Even Compared To Own High Standards
Jul 16What Is Danaher Corporation's (NYSE:DHR) Share Price Doing?
Jun 23Mar Vista - Danaher: Headwinds Are Primarily Cyclical, Growth To Regain Momentum
Jun 20Is Danaher Corporation (NYSE:DHR) Worth US$263 Based On Its Intrinsic Value?
Jun 05Is Danaher (NYSE:DHR) A Risky Investment?
May 21It's Unlikely That Danaher Corporation's (NYSE:DHR) CEO Will See A Huge Pay Rise This Year
May 01Value Vs. Growth? Danaher Says Why Not Both?
Apr 25Danaher: All In On Life Sciences, And Market Update
Mar 27Is Now An Opportune Moment To Examine Danaher Corporation (NYSE:DHR)?
Mar 11Danaher Corporation's (NYSE:DHR) Price Is Out Of Tune With Earnings
Feb 10Bull Case Confirmed: Danaher Is Still One Of The Best Stocks To Buy Long-Term
Jan 30Is Danaher (NYSE:DHR) Using Too Much Debt?
Jan 12My Top 2024 Stock Pick: Danaher
Dec 27Danaher: Poised For Long-Term Growth Despite Near-Term Hurdles
Nov 26RGA Investment Advisors - Danaher: Purity In The Crown Jewel Of Bioprocessing
Nov 19Why Danaher Is One Of My Favorite Long-Term Investments
Oct 26Danaher: Short-Term Headwinds, But Long-Term Tailwinds
Oct 17Should Danaher Investors Sell New Veralto Shares?
Oct 02Danaher Corporation's (NYSE:DHR) Intrinsic Value Is Potentially 18% Below Its Share Price
Sep 30Danaher: A Lost Year
Aug 30Third Point - Danaher: Don't Be Surprised If Growth Rate Moves To Low Teens
Aug 02Danaher: A Compounding Icon At A Fair Price
Jul 25These 4 Measures Indicate That Danaher (NYSE:DHR) Is Using Debt Reasonably Well
Jul 13Calculating The Intrinsic Value Of Danaher Corporation (NYSE:DHR)
Jun 28Danaher: Seizing The Buying Opportunity In A Temporary Bioprocessing Slump
Jun 22At US$238, Is It Time To Put Danaher Corporation (NYSE:DHR) On Your Watch List?
Jun 15Danaher: A Great Chance To Buy This Long-Term Compounder
May 23With EPS Growth And More, Danaher (NYSE:DHR) Makes An Interesting Case
Apr 26Estimating The Intrinsic Value Of Danaher Corporation (NYSE:DHR)
Mar 28Is Now The Time To Look At Buying Danaher Corporation (NYSE:DHR)?
Mar 15Is Danaher (NYSE:DHR) Using Too Much Debt?
Mar 02Danaher ups dividend by 8% to $0.27
Feb 22Shareholder Returns
| DHR | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -1.9% | -0.2% | 0.6% |
| 1Y | 0.7% | 2.3% | 22.9% |
Return vs Industry: DHR underperformed the US Life Sciences industry which returned 2.3% over the past year.
Return vs Market: DHR underperformed the US Market which returned 22.9% over the past year.
Price Volatility
| DHR volatility | |
|---|---|
| DHR Average Weekly Movement | 3.5% |
| Life Sciences Industry Average Movement | 8.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DHR has not had significant price volatility in the past 3 months.
Volatility Over Time: DHR's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1969 | 62,000 | Rainer Blair | www.danaher.com |
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands.
Danaher Corporation Fundamentals Summary
| DHR fundamental statistics | |
|---|---|
| Market cap | US$194.15b |
| Earnings (TTM) | US$4.06b |
| Revenue (TTM) | US$23.57b |
47.4x
P/E Ratio8.2x
P/S RatioIs DHR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DHR income statement (TTM) | |
|---|---|
| Revenue | US$23.57b |
| Cost of Revenue | US$9.48b |
| Gross Profit | US$14.09b |
| Other Expenses | US$10.03b |
| Earnings | US$4.06b |
Last Reported Earnings
Jun 28, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 5.62 |
| Gross Margin | 59.78% |
| Net Profit Margin | 17.21% |
| Debt/Equity Ratio | 34.1% |
How did DHR perform over the long term?
See historical performance and comparison